|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gawlik-Jakubczak T, Matuszewski M and
Biernat W: The metastasis of renal cell carcinoma to the urethra
and local tumor recurrence. Urol Int. doi: 10.1159/000501699.
PubMed/NCBI
|
|
5
|
Yu L, Xiang L, Feng J, Li B, Zhou Z, Li J,
Lin Y, Lv Y, Zou D, Lei Z, et al: miRNA-21 and miRNA-223 expression
signature as a predictor for lymph node metastasis, distant
metastasis and survival in kidney renal clear cell carcinoma. J
Cancer. 9:3651–3659. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rivera-Franco MM and Leon-Rodriguez E:
Delays in breast cancer detection and treatment in developing
countries. Breast Cancer (Auckl).
12:11782234177526772018.PubMed/NCBI
|
|
8
|
Li P, Wong YN, Armstrong K, Haas N, Subedi
P, Davis-Cerone M and Doshi JA: Survival among patients with
advanced renal cell carcinoma in the pretargeted versus targeted
therapy eras. Cancer Med. 5:169–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan KJ, Liu Y, Yang B, Tian XD, Li CR and
Wang B: Prognostic and diagnostic significance of long non-coding
RNA AGAP2-AS1 levels in patients with non-small cell lung cancer.
Eur Rev Med Pharmacol Sci. 21:2392–2396. 2017.PubMed/NCBI
|
|
10
|
Li W, Sun M, Zang C, Ma P, He J, Zhang M,
Huang Z, Ding Y and Shu Y: Upregulated long non-coding RNA
AGAP2-AS1 represses LATS2 and KLF2 expression through interacting
with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell Death
Dis. 7:e22252016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, Yang F, Zhang L, Chen J, Zhao Z,
Wang H, Wu F, Liang T, Yan X, Li J, et al: LncRNA profile study
reveals four-lncRNA signature associated with the prognosis of
patients with anaplastic gliomas. Oncotarget. 7:77225–77236.
2016.PubMed/NCBI
|
|
12
|
Dong H, Wang W, Mo S, Chen R, Zou K, Han
J, Zhang F and Hu J: SP1-induced lncRNA AGAP2-AS1 expression
promotes chemoresistance of breast cancer by epigenetic regulation
of MyD88. J Exp Clin Cancer Res. 37:2022018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hui B, Ji H, Xu Y, Wang J, Ma Z, Zhang C,
Wang K and Zhou Y: RREB1-induced upregulation of the lncRNA
AGAP2-AS1 regulates the proliferation and migration of pancreatic
cancer partly through suppressing ANKRD1 and ANGPTL4. Cell Death
Dis. 10:2072019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Z, Wang Y, Wang L, Yao B, Sun L, Liu
R, Chen T, Niu Y, Tu K and Liu Q: Long non-coding RNA AGAP2-AS1,
functioning as a competitive endogenous RNA, upregulates ANXA11
expression by sponging miR-16-5p and promotes proliferation and
metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res.
38:1942019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qi F, Liu X, Wu H, Yu X, Wei C, Huang X,
Ji G, Nie F and Wang K: Long noncoding AGAP2-AS1 is activated by
SP1 and promotes cell proliferation and invasion in gastric cancer.
J Hematol Oncol. 10:482017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Motzer RJ and Molina AM: Targeting renal
cell carcinoma. J Clin Oncol. 27:3274–3276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Wu Z, Fu X and Han W: Long noncoding
RNAs: Insights from biological features and functions to diseases.
Med Res Rev. 33:517–553. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seles M, Hutterer GC, Kiesslich T, Pummer
K, Berindan-Neagoe I, Perakis S, Schwarzenbacher D, Stotz M, Gerger
A and Pichler M: Current Insights into Long Non-Coding RNAs in
Renal Cell Carcinoma. Int J Mol Sci. 17:5732016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao C, Zhang T, Zhang D, Xie L, Zou X, Lei
L, Wu D and Liu L: The long non-coding RNA, SNHG6-003, functions as
a competing endogenous RNA to promote the progression of
hepatocellular carcinoma. Oncogene. 36:1112–1122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng Z, Zhao F, Zhu D, Han J, Chen H, Cai
Y, Chen Z and Xie W: Long non-coding RNA LUCAT1 promotes
proliferation and invasion in clear cell renal cell carcinoma
through AKT/GSK-3β signaling pathway. Cell Physiol Biochem.
48:891–904. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng Y, Lu S, Xu Y and Zheng J: Long
non-coding RNA AGAP2-AS1 promotes the proliferation of glioma cells
by sponging miR-15a/b-5p to upregulate the expression of HDGF and
activating Wnt/β-catenin signaling pathway. Int J Biol Macromol.
128:521–530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang WK, Carmona-Fontaine C and Xavier
JB: Tumour-stromal interactions generate emergent persistence in
collective cancer cell migration. Interface Focus. 3:201300172013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong M, Cheng H, Song L, Wang W, Wang Q,
Xu D and Xing W: Wogonin suppresses the activity of matrix
metalloproteinase-9 and inhibits migration and invasion in human
hepatocellular carcinoma. Molecules. 23:3842018. View Article : Google Scholar
|
|
24
|
Ramjiawan RR, Griffioen AW and Duda DG:
Anti-angiogenesis for cancer revisited: Is there a role for
combinations with immunotherapy? Angiogenesis. 20:185–204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Viallard C and Larrivée B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manoochehri Khoshinani H, Afshar S and
Najafi R: Hypoxia: A double-edged sword in cancer therapy. Cancer
Invest. 34:536–545. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Braune EB and Lendahl U: Notch -- a
goldilocks signaling pathway in disease and cancer therapy. Discov
Med. 21:189–196. 2016.PubMed/NCBI
|
|
29
|
Li L, Tang P, Li S, Qin X, Yang H, Wu C
and Liu Y: Notch signaling pathway networks in cancer metastasis: A
new target for cancer therapy. Med Oncol. 34:1802017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang Y, Zhou J, Zou D, Hou D, Zhang H,
Zhao J, Li L, Hu J, Zhang Y and Jing Z: Overexpression of Limb-Bud
and Heart (LBH) promotes angiogenesis in human glioma via
VEGFA-mediated ERK signalling under hypoxia. EBioMedicine.
48:36–48. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lugano R, Ramachandran M and Dimberg A:
Tumor angiogenesis: Causes, consequences, challenges and
opportunities. Cell Mol Life Sci. 2019.https://doi.org/10.1007/s00018-019-03351-7
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chappell JC, Payne LB and Rathmell WK:
Hypoxia, angiogenesis, and metabolism in the hereditary kidney
cancers. J Clin Invest. 129:442–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duan MX, Zhou H, Wu QQ, Liu C, Xiao Y,
Deng W and Tang QZ: Andrographolide protects against HG-induced
inflammation, apoptosis, migration, and impairment of angiogenesis
via PI3K/AKT-eNOS signalling in HUVECs. Mediators Inflamm.
2019:61683402019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gallardo E, Méndez-Vidal MJ, Pérez-Gracia
JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I,
García-Del-Muro X, González-Del-Alba A, Grande E and Suárez C: SEOM
clinical guideline for treatment of kidney cancer (2017). Clin
Transl Oncol. 20:47–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
